Dr. Svetlana Kotliarova

Dr. Svetlana Kotliarova

Scientific Review Officer


Division of Translational and Clinical Sciences DTCS
Oncology 2 – Translational Clinical OTC
Study Section:
Cancer Prevention Study Section CPSS

Dr. Svetlana Kotliarova serves as the Scientific Review Officer for Chemo/Dietary Prevention [CDP] Study Section. CDP Study Section reviews applications in the general area of dietary and chemopreventive factors and their use in prevention of cancer.

Dr. Kotliarova received her M.S. in biochemistry and molecular biology from the Novosibirsk University (Russia). Her initial research focus was on the nucleotide excision repair in the laboratory of Grigory Dianov. After receiving her Ph.D. in human genetics from the University of Tokyo (Japan), Dr. Kotliarova completed postdoctoral training under the Japanese Society for Promotion of Science Fellowship in the Department of Human Genetics of the University of Tokyo in the laboratories of Yasuo Nakagome and Katsushi Tokunaga. During that time, she has identified several ethnic-specific loci on the Y chromosome. She then joined the RIKEN Brain Science Institute as a Staff Scientist and studied neurodegenerative disorders in Nobuyuki Nukina’s lab. There she has developed a novel transgenic model for Huntington’s Disease (HD) and has discovered the degeneration of hypothalamus in the HD mouse model. Before joining CSR, Dr. Kotliarova pursued brain tumor research in the Neuro-Oncology Branch at NIH's National Cancer Institute, where she was the Head of the Genomics Core. Her research interests included glioma stem cells, gliomagenesis, genomics and development of new therapies for brain tumors. Dr. Kotliarova was the first to demonstrate a role of the GSK3 in gliomas. Her research is published in highly ranked scientific journals such as Cancer Research, Clinical Cancer Research, Journal of Biological Chemistry, Human Molecular Genetics, and Cancer Cell.